Similar Items: Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- Regional amyloid PET asymmetry and long‐term clinical trajectory in mild cognitive impairment
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- Obstacles and solutions for implementing amyloid‐targeting treatments in Europe
- Travel barriers to amyloid‐targeting infusion access among older adults
- Performing multiple biomarker tests delays initiation of amyloid‐targeting treatments
- White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies